EndoStim, which makes an implantable device to treat gastroesophageal reflux disease, reportedly tables its initial public offering due to poor market conditions.
EndoStim, citing poor market conditions, has tabled its initial public offering it hoped would raise nearly $36 million for its neurostimulation device for gastroesophageal reflux disease, according to Renaissance Capital.
EndoStim had planned to put $10 million of the IPO's proceeds into clinical studies and another $14 million to commercialize the system.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1vYHuZw
Cap comentari:
Publica un comentari a l'entrada